EXTRANODAL LYMPHOMA

Poster number

Title

Submitting author

City and Country

154

PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT

Andrés Ferreri

Milano, Italy

155

Liquid-biopsy based genotyping of Primary Central Nervous System Lymphoma (PCNSL)

Jan-Michel Heger

Cologne, Germany

156

SARS-CoV-2 INFECTION IN 50 PATIENTS WITH PRIMARY CNS LYMPHOMA: PRESENTATION, EFFECTS ON TUMOR TREATMENT AND OUTCOME IN A SERIES OF THE INTERNATIONAL PCNSL COLLABORATIVE GROUP

Andrés Ferreri

Milano, Italy

157

Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Real World (RW) Outcomes of Post-Induction Therapy in the Modern Era

Kevin David

New Brunswick, NJ, USA

158

Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (CNS-PTLD): A 20 years Retrospective Single Center Experience

Noemie Lang*

Toronto, Canada

159

Phase Ib/II study of Lenalidomide, Rituximab, High-dose Methotrexate (R2-MTX) regimen, followed by lenalidomide maintenance in Newly Diagnosed Primary CNS Lymphoma

Yan Zhang

Beijing, China

160

Use of methotrexate, whatever kidney function, with a simple algorithm, radically changes the prognosis of post-transplant CNS lymphomas

Sylvain Choquet

Paris, France

161

Combination of rituximab-lenalidomide-ibrutinib in relapsed/refractory primary CNS lymphoma: a cohort study of the LOC network

Caroline Houillier

Paris, France

162

CAR-T cell therapy in primary central nervous system lymphoma (PCNSL): the experience of the French network for oculo-cerebral lymphomas (LOC)

Sylvain Choquet

Paris, France

163

Lenalidomide and rituximab regimen combined with intravitreal methotrexate followed by lenalidomide maintenance for primary vitreoretinal lymphoma: a prospective phase II study

Yan Zhang

Beijing, China

164

RITUXIMAB-DOSE-ADJUSTED EPOCH (R-da-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES

Theodoros Vassilakopoulos

Athens, Greece

165

Primary Mediastinal B-cell Lymphoma: Intensified regimens do not improve outcomes as compared to RCHOP in a resource-constrained setting

Rodrigo Velasques

São Paulo, Brazil